NCT02626507 2022-02-09Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast CancerHoffman OncologyPhase 1 Unknown18 enrolled
NCT03698383 2021-02-18Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast CancerKorean Cancer Study GroupPhase 2 Unknown15 enrolled